BIOMAT Database Logo BIOMAT Database Logo

Pulmonary surfactant composition early in development of acute lung injury after cardiopulmonary bypass: prophylactic use of surfactant therapy. 1997

P L Haslam, and C S Baker, and D A Hughes, and P D MacNaughton, and N E Moat, and A Dewar, and A Aggarwal, and T W Evans
Cell Biology Unit, National Heart & Lung Institute, Imperial College, London, UK.

Cardiopulmonary bypass surgery (CPB) causes lung injury and at least 2% of adult patients and more children develop the most severe from acute respiratory distress syndrome (ARDS). Pulmonary surfactant deficiency contributes to the pathogenesis of ARDS. It has been proposed that surfactant therapy immediately after CPB might arrest progression to ARDS. However, many patients develop only mild lung injury after CPB. Thus early markers are needed to identify those patients at highest risk to guide selection for treatment. The aim of this study was to determine whether changes in surfactant phospholipids occur, and reflect severity of lung injury within the first few hours after bypass. Because of the relatively low incidence of ARDS in adult patients, this study was conducted using young pigs highly susceptible to bypass-induced lung injury. Eight pigs were given 2 hours bypass. Six controls underwent 'sham' bypass. At 3 h after bypass pulmonary vascular endothelial permeability was assessed by transcapillary leakage of radiolabelled transferrin. A 4 hour broncho-alveolar lavage (BAL) was used to assess intra-alveolar levels of surfactant, inflammatory cells and oedema protein. Bypass caused falls in arterial oxygenation and lung compliance (P < 0.01), but at this early stage in progression of lung injury BAL surfactant phospholipid and albumin levels were within the control range indicating that the alveolar epithelium had not yet suffered major damage. The main abnormalities were increases in vascular endothelial permeability (P < 0.01), BAL neutrophils (P < 0.01), total protein and sphingomyelin (SM) (P < 0.05). Lung histology showed that the main damage was interstitial oedema located around the bronchioles and their associated vessels. A single instilled dose of surfactant phospholipids in 5 animals caused excess in vivo supplementation and did not reduce the early pathophysiologic changes. Our findings suggest that surfactant phospholipid deficiency does not make a major contribution in the initial stages of lung injury after CPB, and that excessive phospholipid supplementation at this stage can be deleterious.

UI MeSH Term Description Entries
D008168 Lung Either of the pair of organs occupying the cavity of the thorax that effect the aeration of the blood. Lungs
D008297 Male Males
D008854 Microscopy, Electron Microscopy using an electron beam, instead of light, to visualize the sample, thereby allowing much greater magnification. The interactions of ELECTRONS with specimens are used to provide information about the fine structure of that specimen. In TRANSMISSION ELECTRON MICROSCOPY the reactions of the electrons that are transmitted through the specimen are imaged. In SCANNING ELECTRON MICROSCOPY an electron beam falls at a non-normal angle on the specimen and the image is derived from the reactions occurring above the plane of the specimen. Electron Microscopy
D010743 Phospholipids Lipids containing one or more phosphate groups, particularly those derived from either glycerol (phosphoglycerides see GLYCEROPHOSPHOLIPIDS) or sphingosine (SPHINGOLIPIDS). They are polar lipids that are of great importance for the structure and function of cell membranes and are the most abundant of membrane lipids, although not stored in large amounts in the system. Phosphatides,Phospholipid
D011506 Proteins Linear POLYPEPTIDES that are synthesized on RIBOSOMES and may be further modified, crosslinked, cleaved, or assembled into complex proteins with several subunits. The specific sequence of AMINO ACIDS determines the shape the polypeptide will take, during PROTEIN FOLDING, and the function of the protein. Gene Products, Protein,Gene Proteins,Protein,Protein Gene Products,Proteins, Gene
D011663 Pulmonary Surfactants Substances and drugs that lower the SURFACE TENSION of the mucoid layer lining the PULMONARY ALVEOLI. Surfactants, Pulmonary,Pulmonary Surfactant,Surfactant, Pulmonary
D012128 Respiratory Distress Syndrome A syndrome characterized by progressive life-threatening RESPIRATORY INSUFFICIENCY in the absence of known LUNG DISEASES, usually following a systemic insult such as surgery or major TRAUMA. ARDS, Human,Acute Respiratory Distress Syndrome,Adult Respiratory Distress Syndrome,Pediatric Respiratory Distress Syndrome,Respiratory Distress Syndrome, Acute,Respiratory Distress Syndrome, Adult,Respiratory Distress Syndrome, Pediatric,Shock Lung,Distress Syndrome, Respiratory,Distress Syndromes, Respiratory,Human ARDS,Lung, Shock,Respiratory Distress Syndromes,Syndrome, Respiratory Distress
D001992 Bronchoalveolar Lavage Fluid Washing liquid obtained from irrigation of the lung, including the BRONCHI and the PULMONARY ALVEOLI. It is generally used to assess biochemical, inflammatory, or infection status of the lung. Alveolar Lavage Fluid,Bronchial Lavage Fluid,Lung Lavage Fluid,Bronchial Alveolar Lavage Fluid,Lavage Fluid, Bronchial,Lavage Fluid, Lung,Pulmonary Lavage Fluid,Alveolar Lavage Fluids,Bronchial Lavage Fluids,Bronchoalveolar Lavage Fluids,Lavage Fluid, Alveolar,Lavage Fluid, Bronchoalveolar,Lavage Fluid, Pulmonary,Lavage Fluids, Alveolar,Lavage Fluids, Bronchial,Lavage Fluids, Bronchoalveolar,Lavage Fluids, Lung,Lavage Fluids, Pulmonary,Lung Lavage Fluids,Pulmonary Lavage Fluids
D002199 Capillary Permeability The property of blood capillary ENDOTHELIUM that allows for the selective exchange of substances between the blood and surrounding tissues and through membranous barriers such as the BLOOD-AIR BARRIER; BLOOD-AQUEOUS BARRIER; BLOOD-BRAIN BARRIER; BLOOD-NERVE BARRIER; BLOOD-RETINAL BARRIER; and BLOOD-TESTIS BARRIER. Small lipid-soluble molecules such as carbon dioxide and oxygen move freely by diffusion. Water and water-soluble molecules cannot pass through the endothelial walls and are dependent on microscopic pores. These pores show narrow areas (TIGHT JUNCTIONS) which may limit large molecule movement. Microvascular Permeability,Permeability, Capillary,Permeability, Microvascular,Vascular Permeability,Capillary Permeabilities,Microvascular Permeabilities,Permeabilities, Capillary,Permeabilities, Microvascular,Permeabilities, Vascular,Permeability, Vascular,Vascular Permeabilities
D002315 Cardiopulmonary Bypass Diversion of the flow of blood from the entrance of the right atrium directly to the aorta (or femoral artery) via an oxygenator thus bypassing both the heart and lungs. Heart-Lung Bypass,Bypass, Cardiopulmonary,Bypass, Heart-Lung,Bypasses, Cardiopulmonary,Bypasses, Heart-Lung,Cardiopulmonary Bypasses,Heart Lung Bypass,Heart-Lung Bypasses

Related Publications

P L Haslam, and C S Baker, and D A Hughes, and P D MacNaughton, and N E Moat, and A Dewar, and A Aggarwal, and T W Evans
Pulmonary injury after cardiopulmonary bypass.
January 2001, Chest,
P L Haslam, and C S Baker, and D A Hughes, and P D MacNaughton, and N E Moat, and A Dewar, and A Aggarwal, and T W Evans
Lung injury after cardiopulmonary bypass.
July 2006, Perfusion,
P L Haslam, and C S Baker, and D A Hughes, and P D MacNaughton, and N E Moat, and A Dewar, and A Aggarwal, and T W Evans
Antioxidant attenuates acute lung injury after cardiopulmonary bypass in rats.
January 2007, Asian cardiovascular & thoracic annals,
P L Haslam, and C S Baker, and D A Hughes, and P D MacNaughton, and N E Moat, and A Dewar, and A Aggarwal, and T W Evans
Pulmonary surfactant in acute lung injury.
January 1999, Critical care medicine,
P L Haslam, and C S Baker, and D A Hughes, and P D MacNaughton, and N E Moat, and A Dewar, and A Aggarwal, and T W Evans
Lung injury and acute respiratory distress syndrome after cardiopulmonary bypass.
September 1999, The Annals of thoracic surgery,
P L Haslam, and C S Baker, and D A Hughes, and P D MacNaughton, and N E Moat, and A Dewar, and A Aggarwal, and T W Evans
Matrix metalloproteinase inhibitor prevents acute lung injury after cardiopulmonary bypass.
July 1999, Circulation,
P L Haslam, and C S Baker, and D A Hughes, and P D MacNaughton, and N E Moat, and A Dewar, and A Aggarwal, and T W Evans
Pulmonary surfactant and cardiopulmonary bypass in infants.
January 2000, The Journal of thoracic and cardiovascular surgery,
P L Haslam, and C S Baker, and D A Hughes, and P D MacNaughton, and N E Moat, and A Dewar, and A Aggarwal, and T W Evans
Pulmonary surfactant and cardiopulmonary bypass in infants
January 2000, The Journal of thoracic and cardiovascular surgery,
P L Haslam, and C S Baker, and D A Hughes, and P D MacNaughton, and N E Moat, and A Dewar, and A Aggarwal, and T W Evans
Pulmonary artery perfusion with protective solution reduces lung injury after cardiopulmonary bypass.
May 2000, The Annals of thoracic surgery,
P L Haslam, and C S Baker, and D A Hughes, and P D MacNaughton, and N E Moat, and A Dewar, and A Aggarwal, and T W Evans
Lung injury after cardiopulmonary bypass: Alternative treatment prospects.
January 2022, World journal of clinical cases,
Copied contents to your clipboard!